FAQs



What does NeoStem do?

NeoStem, Inc. (“NeoStem”) is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

Back to Top


What is NeoStem’s relationship with Progenitor Cell Therapy, LLC?

Progenitor Cell Therapy, LLC (PCT) is a wholly-owned subsidiary of NeoStem, Inc. NeoStem acquired PCT in January, 2011.

Back to Top


What is NeoStem’s relationship with Amorcyte, LLC?

Amorcyte, LLC is a wholly owned subsidiary of NeoStem, Inc.  NeoStem acquired Amorcyte in October, 2011.

Back to Top


What is NeoStem’s relationship with Athelos Corporation?

Athelos Corporation is owned 88.5% by NeoStem, and 11.5% by Becton-Dickinson.

Back to Top


What is NeoStem’s Financial Conflict of Interest Policy?

You can view the Company’s Financial Conflict of Interest Policy by clicking here.

Back to Top


What is NeoStem’s ticker symbol, exchange and CUSIP?

The Company’s common stock is traded on NASDAQ, ticker symbol NBS . The CUSIP for the common stock is 640650404.

Back to Top


What is NeoStem’s fiscal year?

NeoStem’s fiscal year ends on December 31.

Back to Top


Who is NeoStem’s IR contact?

NeoStem, Inc.
Dr. Robin L. Smith, Chairman and CEO
Phone: (212) 584-4174
E-mail: rsmith@neostem.com

Back to Top


Who are NeoStem’s auditor and corporate legal counsel?

NeoStem’s auditor is Grant Thornton LLP. (www.granthornton.com)

NeoStem’s corporate legal counsel is Lowenstein Sandler PC. (www.lowenstein.com)

Back to Top


Who is NeoStem’s transfer agent?

NeoStem’s transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com)

Back to Top


NeoStem - Cell Therapy Development - Investors